Submitted by Elena Manea on Mon, 01/13/2025 - 13:36
Keywords:
HEMODYNAMIQUE
RMN DE FLUX
Exploring radial sampling strategies for fast and reliable flow measurements in MRI by combining realistic numerical simulations and advanced deep learning-based image reconstruction
Project Leader:
INSA Lyon
INSA’s scientific leader:
Bruno SIXOU
The goal of the project is to provide clinicians a fast and reliable, velocity quantification method to explore abnormal blood flow in the most anatomically
INSA Challenge:
Santé Globale et Bioingénierie
Partners:
UNIVERSITÉ DE MONTPELLIER
CNRS
Funding Institution:
ANR
Dates - Duration:
2024-10-01 00:00:00 to 2028-12-01 00:00:00
Funding:
470292
Contact:
bruno.sixou@insa-lyon.fr
Chapo:
Are numerical simulations and deep learning useful to improve the study of blood flow with Flow MRI?
Système cholinergique et pathologie Aß: quels sont les facteurs clés dans la maladie d'Alzheimer?
Project Leader:
INSA LYON
INSA’s scientific leader:
Nathalie Bernoud-Hubac
La maladie d'Alzheimer est la plus fréquente des démences dans la population sénescente. Elle toucherait
environ 10 millions de personnes dans le monde et ce nombre atteindrait 45 millions en 2050 selon l'OMS. Il s'agit
d'une maladie neurodégénérative caractérisée par une perte progressive de la mémoire et des facultés
cognitives, une désorientation spatiale et des changements de comportement. Le facteur de risque génétique
principal est l'allèle 4 du gène APOE (APOE4). Les caractéristiques pathologiques de cette maladie incluent la
INSA Challenge:
Santé Globale et Bioingénierie
Partners:
INSA LYON - LAMCOS
Funding Institution:
REGION AURA
Dates - Duration:
2021-02-01 00:00:00 to 2025-10-01 00:00:00
Funding:
33000
Contact:
nathalie.bernoud-hubac@insa-lyon.f
Chapo:
Proposition d'une nouvelle stratégie thérapeutique.
Prophylaxie personnalisée contre l'arthropathie des patients hémophiles
Project Leader:
INSA LYON
INSA’s scientific leader:
Tao WANG
L'objectif principal de ce projet d’amorçage est de renforcer un consortium existant afin de préparer la soumission d’un projet européen. Ce dernier vise à créer un jumeau virtuel pour améliorer les efforts de recherche clinique en cours et permettre une gestion personnalisée de l'arthropathie chez les patients atteints d'hémophilie sévère. Des ensembles de données complexes et détaillés seront collectés, incluant des données sérologiques, génétiques, d'IRM, d'échographie, de spectrométrie de masse, génomiques et environnementales des patients.
INSA Challenge:
Santé Globale et Bioingénierie
Partners:
UJM
HCL
VIVANTES
HUMANITAS
UDL
UCL_LOUVAIN
Funding Institution:
REGION AURA
Dates - Duration:
2023-06-01 00:00:00 to 2025-09-01 00:00:00
Funding:
20000
Contact:
tao.wang@univ-st-etienne.fr
Chapo:
Consolidons un consortium européen pour lutter contre l'arthropathie chez les patients hémophiles grâce à la technologie de jumeau virtuel
Architecture du chromosome et expression génique chez les bactéries
Project Leader:
INSA LYON-MAP
INSA’s scientific leader:
William NASSER
Bacterial adaptation to environmental changes requires a rapid reorganization of expression pattern of their genome. This adaptive response, which is critical for both bacterial survival and pathogenicity, is mediated by specific transcription factors, DNA supercoiling and global regulators represented by abundant nucleoid-associated-proteins (NAPs), which constrain supercoils and modulate both the chromatin structure and the transcription of numerous genes.
INSA Challenge:
Santé Globale et Bioingénierie
Partners:
INSTITUT PASTEUR-UNITE REGULATION SPATIALE DES GENOMES
Funding Institution:
ANR
Dates - Duration:
2023-10-01 00:00:00 to 2026-09-01 00:00:00
Funding:
513417
Contact:
william.nasser@insa-lyon.fr
Chapo:
Role of the spatial organization of the genome in the control of bacterial infection
Climatology of Chronic Non-ischemic Cardiomyopathy long term prediction from multi-scale data and models
Project Leader:
INRIA
INSA’s scientific leader:
Olivier BERNARD
Non-ischemic chronic cardiomyopathies (NICM) represent a complex group of cardiac diseases, accounting for 40% of heart failure patients. The challenge in classification, diagnosis, and treatment stems from their multifactorial nature and clinical variability. Major subtypes include dilated and hypertrophic cardiomyopathies (DCM and HCM), each with distinct characteristics. These diseases can progress to heart failure and carry a risk of cardiac arrhythmias, including sudden death. Currently, there are no risk stratification scores for these patients.
INSA Challenge:
Santé Globale et Bioingénierie
Partners:
INRIA
HCL
APHM MARSEILLE
Funding Institution:
PIA ANR
Dates - Duration:
2023-07-01 00:00:00 to 2027-08-01 00:00:00
Funding:
1796572
Contact:
olivier.bernard@insa-lyon.fr
Chapo:
Prediction of the evolution of non-ischemic chronic cardiomyopathies through computational models
Elucider et Contrôler les Effets Nanométriques dans les Nanofils de ZnO pour les applicatifs composites piézoélectriques
Project Leader:
CNRS
INSA’s scientific leader:
Lionel PETIT
As a biocompatible semiconductor composed of abundant elements, ZnO has received a huge interest for a wide variety of electronic, optoelectronic, chemical, and biological sensing applications. Thanks to its high PZ coefficients as a semiconductor, the integration of ZnO into PZ devices such as PZ nano-generators and/or pressure/strain sensors has extensively been considered in the last decade.
INSA Challenge:
Santé Globale et Bioingénierie
Partners:
Institut NEEL
LETI
LTM
Funding Institution:
ANR
Dates - Duration:
2023-02-01 00:00:00 to 2027-01-01 00:00:00
Funding:
616850
Contact:
lionel.petit@insa-lyon.fr
Chapo:
IMINEN is a PRC project aiming at elucidating and monitoring nano-sized effects on several properties of ZnO nanowires (NWs), including their piezoelectric (PZ) coefficients, residual & intentional doping, polarity and surfaces for PZ applications
With 1.6 doctors per 1,000 people worldwide and 3.2 doctors per 1,000 people in France, medicine is under immense demographic pressure and providing appropriate access to care to the entire population is still a dream. According to the WHO, 1 in 4 people in Europe are affected by psychiatric disorders during their lifetime. In France, nearly 3 million people are affected by depression each year. An important challenge of artificial intelligence is to facilitate medical diagnoses.
INSA Challenge:
Santé Globale et Bioingénierie
Partners:
HUMAN MATTER
Funding Institution:
ANR
Dates - Duration:
2022-10-01 00:00:00 to 2026-03-01 00:00:00
Funding:
382918
Contact:
celine.robardet@insa-lyon.fr
Chapo:
Improving psychiatric screening with artificial intelligence
Revêtement adhérent d'apatite biomimétique fonctionnalisée pour implants en PEEK
Project Leader:
CIRIMAT_INP TOULOUSE
INSA’s scientific leader:
Ana-Maria TRUNFIO-SFARGHIU
Medical implants replace dysfunctional or missing body parts to maintain physiological functions. The associated market is growing by 4%/year. However, the key factor restraining the market is high implant costs. In this view, PEEK and CRF-PEEK due to biocompatibility, mechanical properties similar to that of bone and radiolucency, are increasingly used instead of metals. But, these biomaterials are bionert inducing a very limited osseointegration, which is THE expectation for bone implants.
INSA Challenge:
Santé Globale et Bioingénierie
Partners:
URCA
ENIT
UTBM
Funding Institution:
ANR
Dates - Duration:
2022-10-01 00:00:00 to 2027-01-01 00:00:00
Funding:
615784
Contact:
ana-maria.sfarghiu@insa-lyon.fr
Chapo:
Adherent biomimetic apatite coating on PEEK implants to promote bone growth
Stratification du risque de l'embolie pulmonaire par modelisation de l'arbre vasculaire pulmonaire
Project Leader:
INSA LYON
INSA’s scientific leader:
Odyssée MERVEILLE
Pulmonary embolism (the blockage of a pulmonary artery by a blood clot) is the third cause of cardiovascular death in Europe. Upon diagnosis confirmation, clinicians evaluate the patient prognosis based on risk stratification models. The management of patient, thus its outcome, highly depend on this risk stratification. Recent studies confirmed that patient stratification based on computed tomography pulmonary angiogram (CTPA) are not well correlated to patient prognosis.
INSA Challenge:
Santé Globale et Bioingénierie
Funding Institution:
ANR
Dates - Duration:
2023-01-01 00:00:00 to 2026-12-01 00:00:00
Funding:
279046
Contact:
odysse.merveille@insa-lyon.fr
Chapo:
Prédiction du risque de patients atteints d’embolie aigue à partir de biomarqueurs fonctionels et morphologiques